Cost-effectiveness of noninvasive ventilation for chronic obstructive pulmonary disease-related respiratory failure in Indian hospitals without ICU facilities

Shraddha P Patel, Margarita E Pena, Charlene Irvin Babcock

Department of Emergency Medicine, St. John Hospital and Medical Center, Wayne State University, Detroit, Michigan, USA

ABSTRACT

Introduction: The majority of Indian hospitals do not provide intensive care unit (ICU) care or ward-based noninvasive positive pressure ventilation (NIV). Because no mechanical ventilation or NIV is available in these hospitals, the majority of patients suffering from respiratory failure die. Objective: To perform a cost-effective analysis of two strategies (ward-based NIV with concurrent standard treatment vs standard treatment alone) in chronic obstructive pulmonary disease (COPD) respiratory failure patients treated in Indian hospitals without ICU care. Materials and Methods: A decision-analytical model was created to compare the cost-effectiveness for the two strategies. Estimates from the literature were used for parameters in the model. Future costs were discounted at 3%. All costs were reported in USD (2012). One-way, two-way, and probabilistic sensitivity analysis were performed. The time horizon was lifetime and perspective was societal. Results: The NIV strategy resulted in 17.7% more survival and was slightly more costly (increased cost of $101 (USD 2012) but resulted in increased quality-adjusted life-years (QALYs) (1.67 QALY). The cost-effectiveness (2012 USD)/QALY in the standard and NIV groups was $78/QALY ($535.02/6.82) and $75/QALY ($636.33/8.49), respectively. Incremental cost-effectiveness ratio (ICER) was only $61 USD/QALY. This was substantially lower than the gross domestic product (GDP) per capita for India (1489 USD), suggesting the NIV strategy was very cost effective. Using a 5% discount rate resulted in only minimally different results. Probabilistic analysis suggests that NIV strategy was preferred 100% of the time when willingness to pay was >$250 2012 USD. Conclusion: Ward-based NIV treatment is cost-effective in India, and may increase survival of patients with COPD respiratory failure when ICU is not available.

KEY WORDS: Chronic obstructive pulmonary disease, cost-effectiveness of ward-based NIV, no access to intensive care unit care, noninvasive positive pressure ventilation, respiratory failure, USD/quality-adjusted life-year

INTRODUCTION

A cost-effective analysis is important in all public health decision-making, and critical in low- and middle-income countries where health care resources are severely limited and rationing decisions are necessary.[1-6] Although some of the hospitals in these low-income countries have intensive care capabilities, many more do not have these advanced capabilities.[7] In hospitals without intensive care units (ICUs), survival of patients with respiratory failure is dismal as no rescue mechanical ventilation is possible. The only option available for these moribund patients is transfer to a hospital with an ICU, if one is even available.

Because of financial constraints, it may be important for low-income countries to consider less traditional mechanisms to treat respiratory failure patients. Mechanical ventilation is expensive, with cost-effectiveness estimates of 29,000–110,000 $/QALY, (1994 USD).[6,9] This is likely not a reasonable cost expenditure for many low-income countries. However, these studies estimating cost effectiveness were performed in developed countries where the cost may be substantially inflated compared to the cost of critical care and mechanical ventilation in low-income countries.[10,11]
Newer treatments for respiratory failure include noninvasive positive pressure ventilation (NIV) initially followed by mechanical ventilation for NIV failures.\textsuperscript{[12-15]} This approach has been shown to reduce the risk of ICU mortality and complications, and reduced length of stay in conditions such as chronic obstructive pulmonary disease (COPD).\textsuperscript{[12-15]} Additionally, several studies have documented NIV as cost-effective.\textsuperscript{[16]} As noninvasive ventilation can occur safely outside the ICU, this modality may be a potential option in hospitals without ICU facilities.\textsuperscript{[17-19]} In this approach, although rescue mechanical ventilation for noninvasive ventilation failures would not be available, it may still offer a survival advantage at a reasonable cost for many patients.

The purpose of this study is to compare the cost-effectiveness of the use of ward-based NIV plus standard treatment to standard treatment alone in COPD-related respiratory failure patients in India.

\textbf{MATERIALS AND METHODS}

This study was submitted to the Investigational Review Board of St. John Hospital and Medical Center and was determined to be exempt from review.

Following recommendations from the US Public Health Service Panel on Cost-effectiveness in Health and Medicine and the American Thoracic Society (ATS) workgroup, the analysis was conducted from the societal perspective, with a lifetime time horizon and the assumption of a discount rate of 3% for costs and health effects.\textsuperscript{[20,21]} Additionally, a second analysis was performed using a 5% discount rate.\textsuperscript{[20]} The Indian Consumer Price Index (CPI) was used to inflate historical cost estimates to 2012. All currency is reported in US dollars (2012).

\textbf{Model and estimates}

The model used in the analysis was a decision tree with one-way sensitivity analysis, two-way sensitivity analysis, and probabilistic (Monte Carlo) analysis. Estimates for variables in the model were drawn from the literature. Figure 1 reveals the decision tree utilized in the analysis.

![Figure 1: Decision tree](image)

Table 1 reveals the estimates used in the model, and the sources.

\textbf{Mortality estimates}

As it was assumed that mechanical ventilation was not available, mortality estimates in both groups (NIV and standard treatment) were estimated from the proportion of individuals requiring rescue mechanical intubation in the studies comparing NIV (with standard care) and standard care alone patients. Several authors have performed meta-analysis of NIV and standard treatment in COPD respiratory failure patients, and reported the rescue intubation rate.\textsuperscript{[12-14,22]} Although the estimates were all similar, as we needed to choose one, we used the intubation rate from the most recent meta-analysis, which also had the largest number of patients and included all the studies from the previous meta-analysis.\textsuperscript{[13]} For sensitivity analysis, we used means and standard deviations (SDs). The mean and SD were also used in the probabilistic analysis, with a beta distribution.

\textbf{Total length of stay (LOS) estimates}

All studies comparing NIV with the standard treatment found that the NIV group had a shorter total LOS. Data from Indian references were preferred as local practices are likely to be representative of true Indian LOS. Only two Indian randomized trials of COPD getting NIV or standard treatment were found. Prasad (2007, randomized, \(N = 19\), LOS standard treatment = 13.33± 4.69 days and NIV treatment = 9.63± 1.41 days) and Khilnani (2010, randomized, \(N = 40\), LOS standard treatment = 17.8± 2.6 days and NIV treatment, LOS = 9.4± 4.3 days) were both reviewed.\textsuperscript{[30,31]} No data were provided on LOS for standard or NIV treatment groups in patients not needing rescue intubation, and both Indian studies had >50% intubation rate (which increases LOS). One older study (Brochard, 1995, randomized, \(N = 85\), France based) noted total LOS for Standard treatment not requiring intubation of 20 (±6) days and NIV treatment not requiring intubation of 17 (± 9) days (difference of 3 days).\textsuperscript{[32]}

Estimates from both the Indian studies were very close to prevent any bias in the study against NIV treatment.\textsuperscript{[30,31]} This was additionally supported by the older non-Indian study, which noted a difference in LOS of 3 days, and the large recent meta-analysis, which found that the difference in LOS for all the 11 studies included was 2.68 days.\textsuperscript{[13,36]}

For sensitivity analysis, a range of ± 50% LOS was chosen. In probabilistic analysis, the means and SDs were used with a normal distribution. Regarding the LOS from all studies conducted so far, comparison of NIV to standard treatment has revealed that the NIV treatment group
Table 1: Estimates and sources used in the model

| Variable | Point estimate | Notes, assumptions, sources |
|----------|----------------|-----------------------------|
| Probability of death in NIV* treatment | 0.101 (50/496) 95% CI**=0.0771-0.1.306 (modified Wald method) | References reviewed: McCurdy, Ram, Keenan, Agarwal, and Lightowler.[13-14,22,23] Estimates used came from McCurdy as the meta-analysis was more recent (2012) and included the largest sample size (496). [13] Mortality rate was estimated as the intubation rate in the NIV treatment arm. The mean and confidence intervals used in sensitivity analysis and beta distribution were used in probabilistic analysis |
| Probability of death in standard treatment | 0.278 (140/504) 95% CI=0.2404-0.3185 (modified Wald method) | References reviewed: Plant, McCurdy, and Ram, Keenan, and Lightowler. [12,14,17,22] Estimates used came from McCurdy as this meta-analysis was most recent (2012) and included the largest sample size (504). [13] Mortality rate was estimated as intubation rate in the standard treatment arm. The mean and confidence interval used in sensitivity analysis with beta distribution was used in Monte Carlo analysis |
| Cost ward hospitalization in standard treatment group, and cost ward treatment after NIV in NIV group | 12.82 USD/day | References reviewed include: Tabish (costs per all hospitalizations, not COPD specific), Dror (costs per all hospitalization, not COPD***-specific), Cooke (US-based cost analysis), Shah (costs assumed were equal to hospital revenue), Plant (UK-based cost analysis), Murthy (only had total hospitalization costs, not per day), and Veettil. [13-16] We choose to use Veettil data for estimates as data from 2012, India-specific, COPD-specific, available per day, and based on prospective micro-cost analysis technique. Data were obtained from a government hospital. [29] For sensitivity analysis, the cost of hospitalization varied ±50% used, and for probabilistic analysis, triangular distribution with ±50% was used |
| QALY**** NIV and standard treatment in survivors after discharge | QALY=11.7 Years lived=15 | Linko study of utilities of patients after respiratory failure was a source of QALY and life expectancy (after treatment with only NIV). [39] It was assumed that QALY was not different for survivors of either standard or NIV care after discharge. For sensitivity analysis and for Monte Carlo analysis, ±50% QALY used. For years, in sensitivity analysis, 0-25 years were used, and for probabilistic analysis 0-25 years were used with a triangular distribution |
| Total days hospitalized (LOS=length of stay) in standard and NIV treated survivors | Standard treatment: 13.33±4.69 days NIV treatment 9.63±1.41 days | Data from Indian references were preferred as local practices are likely to be representative of true Indian LOS. Two Indian randomized trials of COPD getting NIV or standard treatment were reviewed Prasad R (2007, randomized, N=19, LOS standard treatment=13.33±4.69 days and NIV treatment=9.63+/-.1.41 days) and Khilnani (2010, randomized, N=40, LOS standard treatment=17.8+/-.2.6 days and NIV treatment LOS=9.4±4.3 days). No recent data were available on LOS for standard treatment or NIV treatment in those not intubated, and both studies had >50% intubated (which increases ave LOS). [30,31] One older study (Brochard, randomized, N=85, 1995) noted that total LOS for standard treatment did not need intubation of 20±6 days and NIV treatment did not require intubation of 17±9 days. [32] The difference between the two groups was 3 days, providing additional support for using the Prasad estimates (difference in his study was 3.7 days). In sensitivity analysis, a range of +/- 50% was chosen. In probabilistic analysis, the means and standard deviations were used with a normal distribution. The LOS from all studies ever conducted, comparing NIV to standard treatment have found that the NIV treatment group always had a lower LOS. Because of a larger standard deviation in standard treatment LOS, it may be possible in probabilistic analysis for values chosen in LOS standard treatment to be less than the values selected for LOS NIV treatment. As this is not realistic, the “if” function was used in probabilistic analysis such that if the LOS in the standard treatment group was less than LOS in the NIV group, the LOS of the NIV treatment group would be equivalent to the LOS of the standard treatment group. Days receiving NIV | 4 | Only one study was found that provided data on the number of days of NIV in COPD respiratory failure patients (who did not need rescue intubation (Brochard, 1995)). [32] In this study, patients were on NIV for a mean of 4 days (SD=4). As this was the only estimate available, it was the one used. This was a reasonable assumption as the number of days in previous studies (that did not separate out those patients needing rescue intubation) was 3-4 days. For sensitivity analysis, 0–6 days was used. For probabilistic analysis, the mean and standard deviations were used [4(4) days]. To prevent a negative value chosen for days of NIV, the MAX function was utilized such that if a negative value was selected in probabilistic analysis, a zero (i.e., less than 1 day) would be utilized |
| Days of standard treatment before death | 12 | Data from Indian references were preferred as local practices are likely to be representative of true LOS. Indian studies (Khilnani, Prasad) were reviewed. [30,31] The number of days till death was assumed to be the number of days before mechanical ventilation. Although not specifically reported, both studies noted either rapid improvement with treatment (both the standard group and NIV treatment group) or rapid decline so that by 24 h the majority of the patients needing intubation were intubated. Khilnani noted rapid deterioration in standard treatment patients needing intubation but less rapid deterioration in NIV patients. In this analysis, 1 day was chosen for standard treatment and 2 days for NIV treatment. In sensitivity analysis, a range of 0-3 days for standard treatment and a range of 0-4 days for NIV was used. [31] |
| Days of NIV before death | | |
| Willingness to pay | 4,467 USD | WHO-CHOICE: initiative for cost-effectiveness recommends 3x GDP per capita as considered cost-effective. The Indian World Bank, 2012 estimate of 1489 (USD) and multiplied times 3 [13-31] |

Contd...
always had a lower LOS. Because of larger SD in standard treatment LOS, it may be possible in an iteration of the probabilistic analysis for the value chosen in LOS standard treatment to be less than the value selected for LOS NIV treatment. As this is not realistic, the “if” function was used in the probabilistic analysis such that if the value chosen for LOS in the standard treatment group was less than value chosen for LOS in the NIV group, then the value for LOS in the NIV group used in that iteration of the probabilistic analysis would be the LOS of the standard treatment group (making the LOS equivalent in both groups for that iteration of the probabilistic analysis).

Days on NIV
Only one study was found that provided data on the number of days of NIV in COPD respiratory failure patients (that did not need rescue intubation).\[^{32}\] In this study, patients were on NIV for a mean of 4 days (SD = 4). For sensitivity analysis, 0–6 days was used. For probabilistic analysis, mean and SDs were used.

Days before the death of patients in the NIV and standard treated groups
Data from Indian references were preferred as local practices are likely to be representative of the actual number of days before death. As described earlier, only two Indian randomized trials of COPD getting NIV or standard treatment were found.\[^{30,31}\] The number of days till death was assumed to be the number of days before mechanical ventilation. Although not specifically reported, both studies noted either rapid improvement with treatment (both standard and NIV treatment groups) or rapid decline so that by 24 h, the majority needing intubation had been intubated. One study also noted a more rapid deterioration in the standard treatment patients needing intubation and less rapid deterioration in NIV patients.\[^{31}\] Other studies were also reviewed but no specific data were provided on days before intubation.\[^{12,13,15,22,31,36,37}\] In this analysis, 1 day (range of 0–3) was chosen for the standard treatment group and 2 days (range 0–4) was chosen for the NIV treatment group. To test the impact of this assumption, two-way sensitivity was performed.

Cost estimates
The cost of health care in India, even hospital-based health care, is much less expensive than in the US and other developed countries.\[^{38}\] There were numerous cost estimates available for hospitalization cost.\[^{24-28}\] We chose to use the most recent cost analysis.\[^{28}\] In Indian studies, all NIVs were performed in the ICU. The cost for noninvasive ventilation in the wards was not available for Indian hospitals. There was a cost comparison study for ward noninvasive ventilation versus ward standard treatment that was performed in England.\[^{17}\] In this English study, the noninvasive ventilation group in the wards had 30% higher costs than standard care in the wards. As this was our best estimate, for this study, we added 30% to the Indian cost of standard treatment in the wards to estimate the cost for noninvasive ventilation in the wards in India. In all of the cost sensitivities and probabilistic analyses, we assumed the cost could vary ±50%.

To determine the chronic costs for moderate to severe COPD, an Indian study was used (1320 Rupees in 2001) and the Indian Consumer Price Indicator (CPI) calculator was used to inflate to 2012 rupees (INR).\[^{27,34}\] Currency converter used to convert from INR to USD.\[^{35}\] For sensitivity and probabilistic analysis, ±50% was used. The TreeAge “annuity” function was used to discount into the future the yearly costs of COPD treatment and QALY’s with a 3% discount rate, with a second analysis done at 5% discount rate.

Discount rate and willingness to pay
As recommended by the reference case, a discount rate of 3% was used, with a second analysis at 5%.\[^{20}\] Willingness to pay (WTP) estimate was based on 3x gross domestic product (GDP) per capita, as suggested by the World Health Organization (WHO).\[^{4}\]

QALY estimates
We made the assumption that the QALY’s were equivalent in standard and NIV treatment groups after discharge. This assumption is supported by a study evaluating standard and non-invasive ventilation for COPD patients in India that found no difference at 4–6 weeks in blood gas parameters and pulmonary function variables.\[^{30}\] It is also intuitive that once discharged alive, there is no difference between the two groups as there is no evidence showing that using NIV or not using NIV causes any long-term negative consequences. QALY estimates came from a study that measured QALY and survival years in 105 COPD respiratory failure patients treated only with
NIV or standard therapy. As the cost of treatment for COPD was discounted in the future (using the annuity function in TreeAge), the QALY was also discounted in the future. For sensitivity analysis and probabilistic analysis, ±25% was used.

**Statistical analysis**

Cost-effectiveness analysis, one-way sensitivity [incremental cost effectiveness ratio (ICER)], and two-way sensitivity analysis (mortality rates, days till death, and LOS in both strategies) were performed. Monte Carlo (probabilistic) sensitivity was performed with 50,000 iterations.

Analyses were conducted using software (TreeAge Pro 2014; Williamstown, MA, USA). All costs WERE inflated using Indian Consumer Price Index and discounted in the future using 3% discount rate. A secondary analysis was also performed assuming a future 5% discount rate.

**RESULTS**

The mortality rate in these strategies (i.e. the rescue intubation rate from the largest meta-analysis) was 0.101 for the NIV group and 0.278 for the standard treatment group. Table 2 reveals the ICER. The cost (USD 2012)/QALY for the standard treatment and the NIV treatment were $78/QALY ($535.02/6.82) and $75/QALY ($636.33/8.49), respectively, and did not change much in the probabilistic analysis [Table 3]. The NIV group was slightly more expensive (by approximately 100 USD) but resulted in increased effectiveness (QALY increased by 1.67 QALY). ICER was only $61 USD/QALY. This was substantially lower than the GDP per capita for India (1489 USD), suggesting the NIV strategy was very cost-effective.

A two-way sensitivity analysis varying the probability of death in both groups at the same time (while holding all other variables constant) is shown in Figure 4. Notably, the range of the NIV strategy was preferred throughout the entire range of the standard treatment probabilities. However, to determine what death probabilities would cause the standard treatment strategy to be preferred, the ranges for possible death were made equivalent. When this was done, it was clear that the strategy preferred was always the NIV strategy until the death rate in the

| Strategy          | Discount (%) | Cost   | Incremental cost | Effectiveness (QALY**) | Incremental Eff | Cost/Effectiveness | ICER*** |
|-------------------|--------------|--------|------------------|------------------------|----------------|-------------------|---------|
| Standard treatment| 3            | 535.06 |                  | 6.82                   |                | 78                | **4467** |
| NIV treatment     | 3            | 636.33 | 101.27           | 8.49                   | 1.67           | 75                | 61      |
| Standard treatment| 5            | 485.91 |                  | 6.0                    |                | 81                |         |
| NIV Treatment     | 5            | 575.12 | 89.21            | 7.47                   | 1.47           | 77                | 61      |

*WTP: Willingness to pay, **QALY: Quality-adjusted life-year, ***ICER: Incremental cost-effectiveness ratio
NIV group was equal to the death rate in the standard treatment [Figure 4]. As all studies conducted to date have found a decreased intubation rate (which is the marker for death in this model that assumes no ICU facilities available so that those needing intubation would die) in the NIV group, this again supports the NIV treatment. Additionally, this is intuitive as the cost of NIV treatment is more than the cost of standard treatment; hence, when the mortality rates become equal, it would be the point that would make the standard treatment more cost-effective (same probability of death but less expensive).

Two-way sensitivity analysis evaluating the impact of varying the days hospitalized in the two groups found that the NIV strategy was preferred through the entire range, even when the total days hospitalized for NIV was more than for standard treatment. Two-way sensitivity analysis on the number of days before death in both the groups also found the NIV strategy to be the preferred strategy through the ranges.

Figure 5 reveals the results of the cost-effectiveness acceptability curve. Figure 6 reveals the incremental cost-effectiveness results from the probabilistic analysis (the ellipse is the 95% confidence interval). NIV was the preferred strategy and in some of the iterations, was not only cost-effective (results located below 0 cost where the NIV strategy was less costly) but more effective as well.

**DISCUSSION**

This cost-effectiveness analysis pertains to the specific population of COPD patients suffering from respiratory failure who were hypothetically treated in an Indian hospital without access to any ICU facilities. Using mortality information alone (when mortality is assumed to occur at the point of rescue intubation in published data), the noninvasive ventilation strategy would save lives...
and would be cost-effective. The noninvasive ventilation strategy was slightly more costly in comparison to standard treatment but had improved effectiveness (more QALYs). According to the WHO Choosing Interventions that are Cost-Effective (CHOICE) initiative, interventions are considered very cost-effective if the cost-effectiveness per year is less than the GDP per capita, which for India is approximately 1,489 (USD 2012). The NIV strategy had cost-effectiveness of only 61 (USD 2012)/QALY (636.33/8.49), which is only 4% of the Indian GDP/capita. Although it may not be appropriate to extrapolate the cost-effectiveness of NIV to every low-income country, the fact that the cost estimate/QALY was so low suggests that there may be additional opportunities for noninvasive ventilation in other low-income countries when mechanical ventilation is not available.

In India, there is still a critical shortage of ICU beds; there is an estimated need of 5 million ICU beds annually but only 70,000 are available. One-analysis of Indian ICUs found that medical professionals in small hospitals managed 40% of the inpatient beds with limited facilities. The potential for noninvasive ventilation to improve health care in India may be significant.

This analysis focused on a specific population—COPD patients with respiratory failure. Some studies reveal lower mortality, less complications (pneumonia, sepsis, etc.), and lower LOS in NIV treated patients. Some other conditions [acute respiratory distress syndrome (ARDS), acute respiratory infections] may or may not benefit from noninvasive ventilation. One recent study estimated the cost for hospitalization for acute respiratory infections was substantial at $54.00–355.00 (USD). The addition of NIV for respiratory failure in these patients may positively impact this expenditure. However, additional evaluations are necessary before the cost-effectiveness of noninvasive ventilation can be extrapolated in other conditions.

Several studies that were used for estimates provided NIV in the ICU setting. This cost analysis assumed that care would be provided in the ward, as several studies (including one India-based study) have suggested this is safe and effective. Ward-based noninvasive ventilation is becoming more accepted in India, which makes this strategy more realistic.

Economic consequences of this strategy that contribute to increased cost in the NIV group include less mortality and therefore, more cost after hospitalization in the higher proportion of survivors. However, even with increased survival, the incremental cost-effectiveness was only $61 (2012 USD).

One limitation in this study is that the cost-effectiveness analysis is based on estimates drawn from the literature. Several estimates had large variances associated with them. As suggested by the ICER tornado diagram [Figure 3], several parameters where estimations were based on assumptions (days of NIV before death, days of standard treatment before death, and days of NIV) were not critical to the cost analysis. Additionally, even with the large variance, the ICER never crossed 0 in the tornado diagram.

In order to address some of the limitations arising out of using literature-based parameters, Indian-based estimates were used when available. Additionally, estimates varied widely in the probabilistic analysis and the noninvasive ventilation strategy was still preferred. While the best estimates for cost-effectiveness analysis would ideally come from a large randomized controlled trial from different hospitals in India, this analysis may provide the rationale for perusing that type of analysis.

CONCLUSION

Cost effectiveness analysis may prove a powerful tool in addressing the difficulty of traditional ICU health care in low- and middle-income countries. This analysis establishes preliminary evidence for the cost-effectiveness of ward-based NIV treatment for COPD-induced respiratory failure in hospitals without ICUs in India. In this analysis, we found that noninvasive ventilation treatment was cost-effective at 61 (USD, 2012)/QALYs, substantially less than 1 xGDP/QALY, which in India is 1489 (USD, 2012). As 40% of the hospitals in India have no ICU, ward-based noninvasive ventilation may become a crucial new option to provide some life-saving respiratory support. Future research needs to assess the cost-effectiveness of noninvasive treatment in other low- and middle-income countries, as the potential benefits may be substantial.

ACKNOWLEDGEMENT

We would like to thank all the authors of the articles listed at in the reference section.

REFERENCES

1. Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA: An update on the growth and composition of the literature. Med Care 1993;31(Suppl):JS1-11, JS18-149.
2. Chisholm D, van Ommeren M, Ayuso-Mateos JL, Saxena S. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry 2005;187:559-67.
3. Warner KE, Hutton RC. Cost-benefit and cost-effectiveness analysis in health care: Growth and composition of the literature. Med Care 1980;18:1069-84.
4. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low- and middle-income countries: A review of the debates surrounding decision rules. Pharmacoeconomics 2009;27:903-17.
5. Walker D, Fox - Rushby JA. Economic evaluation of communicable disease interventions in developing countries: A critical review of the published literature. Health Econ 2000;9:681-98.
6. Adam T, Lim SS, Mehta S, Bhutta ZA, Fogstad H, Mathai M, et al. Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries. BMJ 2005;331:1107.
7. Baker T. Critical care in low - income countries. Trop Med Int Health 2009;14:143-8.
8. Cooke CR. Economics of mechanical ventilation and respiratory failure. Crit Care Clin 2012;28:39-55, vi.
9. Flaatten H, Kvåle R. Cost of intensive care in a Norwegian University Hospital 1997-1999. Crit Care 2003;7:72-8.
Patel, et al.: Non-invasive ventilation for COPD

10. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease Control Priorities in Developing Countries. Washington (DC): World Bank Publications; 2006. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11784/. [Last accessed on 2015 Jun 15].

11. Parikh CR, Karnad DR. Quality, cost, and outcome of intensive care in a public hospital in Bombay, India. Crit Care Med 1999;27:1754-9.

12. Ram FS, Picot J, Lightowler J, Wedzicha J. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004;CD004104.

13. McCurdy BR. Noninvasive positive pressure ventilation for acute respiratory failure patients with chronic obstructive pulmonary disease (COPD): An evidence-based analysis. Ont Health Technol Assess Ser 2012;12:1-102.

14. Keenan SP, Mehta S. Noninvasive ventilation for patients presenting with acute respiratory failure: The randomized controlled trials. Respir Care 2009;54:116-26.

15. Keenan SP, Sinuff T, Burns KE, Muscedere J, Kutsogiannis J, Mehta S, et al.; Canadian Critical Care Trials Group/Canadian Critical Care Society Noninvasive VentilationGuidelines Group. Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting. CMAJ 2011;183:E195-214.

16. Keenan SP, Gregor J, Sibbald WJ, Cook D, Gafni A. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: More effective and less expensive. Crit Care Med 2000;28:2094-102.

17. Plant PK, Owen JJ, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: A multicentre randomised controlled trial. Lancet 2006;368:1931-3.

18. Dikensoy O, Ikidag B, Filiz A, Bayram N. Comparison of non-invasive ventilation and standard medical therapy in acute hypercapnic respiratory failure: A randomised controlled study at a tertiary health centre in SE Turkey. Int J Clin Pract 2002;56:85-8.

19. Bott J, Carroll MP, Conway JH, Keilty SE, Ward EM, Brown AM, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993;341:1555-7.

20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.

21. Understanding costs and cost-effectiveness in critical care: Report from the second American Thoracic Society workshop on outcomes research. Am J Respir Crit Care Med 2002;165:540-50.

22. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003;326:185.

23. Agarwal R, Aggarwal AN, Gupta D. Role of noninvasive ventilation in acute lung injury/acute respiratory distress syndrome: A proportion meta-analysis. Respir Care 2010;55:163-60.

24. Tabish SA, Mustafa A, Rangrez R. Hospital accounting based cost studies: Indian experience. J Acad Hosp Adm 2001;13:7-9.

25. Dorr DM, van Putten-Rademaker O, Koren R. Cost of illness: Evidence from a study in five resource-poor locations in India. Indian J Med Res 2008;127:347-61.

26. Shah U. Quality and cost of healthcare: An Indian prospective an assessment of direct cost of quality across hospitals in India. Management in Health 2011;15:23-30.

27. Murthy KJ, Sastry JG. Economic Burden of Chronic Obstructive Pulmonary Disease: Burden of Disease in India. New Delhi: National Commission on Macroeconomics and Health; 2005. p. 264.

28. Veettil SK, Salmiah M, Rajiah K, Suresh Kumar BR. Cost of acute exacerbation of COPD in patients attending government hospital in Kerala, India. Int J Pharm Pharm Sci 2012;4:639-61.

29. Linko R, Suojaranta-Vilinen R, Karlsson S, Ruokonen E, Varpula T, Pettia V; FINNALL study investigators. One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure. Crit Care 2010;14:R60.

30. Prasad R, Rout A, Garg R, Kushwaha RA, Ahuja RC. An open randomized controlled trial of noninvasive positive pressure ventilation in patients of acute on chronic hypercapnic respiratory failure in a general respiratory ward setting. Lung India 2007;24:132-8.

31. Khilnani GC, Saikia N, Banga A, Sharma SK. Non-invasive ventilation for acute exacerbation of COPD with very high PaCO2 (2): A randomized controlled trial. Lung India 2010;27:125-30.

32. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rausa A, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333:817-22.

33. The World Bank. Available from: http://www‑wds.worldbank.org/. [Last accessed on 2015 Jun 15].

34. Inflation Calculator. Available from: http://www.fxtop.com/en/ inflation-calculator.php. [Last accessed on 2015 Jun 15].

35. The Currency Converter. Available from: http://www.coinnmill.com/ INR_USD.html. [Last accessed on 2015 Jun 15].

36. Brochard L, Mancebo J, Elliott MW. Noninvasive ventilation for acute respiratory failure. Eur Respir J 2002;19:712-21.

37. Agarwal R, Gupta R, Aggarwal AN, Gupta D. Noninvasive positive pressure ventilation in acute respiratory failure due to COPD vs other causes: Effectiveness and predictors of failure in a respiratory ICU in North India. Int J Chron Obstruct Pulmon Dis 2008;3:737-43.

38. Yeolekar ME, Mehta S. ICU care in India—Status and challenges. J Assoc Physicians India 2008;56:221-2.

39. Ghosh S. Ethics and economics of ICU care in India. Pulmon 2010;12:2-4.

40. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet 2009;374:250-9.

41. Cooke CR, Kahn JM, Watkins TR, Hudson LD, Rubenfeld GD. Cost-effectiveness of implementing low-tidal volume ventilation in patients with acute lung injury. Chest 2009;136:79-88.

42. Sinuff T, Cook DJ. Health technology assessment in the ICU: Noninvasive positive pressure ventilation for acute respiratory failure. J Crit Care 2003;18:59-67.

43. Peash SK, Purakayastha DR, Koul PA, Dawood FS, Saha S, Amarchand R, et al. The cost of acute respiratory infections in Northern India: A multi-site study. BMC Public Health 2015;15:330.

How to cite this article: Patel SP, Pena ME, Babcock CI. Cost-effectiveness of noninvasive ventilation for chronic obstructive pulmonary disease-related respiratory failure in Indian hospitals without ICU facilities. Lung India 2015;32:549-56.

Source of Support: Nil, Conflict of Interest: None declared.